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Abstract
Accumulating evidence suggests that neurons prone to degeneration in Alzheimer's Disease (AD)
exhibit evidence of re-entry into an aberrant mitotic cell cycle. Our laboratory recently
demonstrated that, in a genomic amyloid precursor protein (APP) mouse model of AD (R1.40),
neuronal cell cycle events (CCEs) occur in the absence of beta-amyloid (Aβ) deposition and are
still dependent upon the amyloidogenic processing of the amyloid precursor protein (APP). These
data suggested that soluble Aβ species might play a direct role in the induction of neuronal CCEs.
Here, we show that exposure of non-transgenic primary cortical neurons to Aβ oligomers, but not
monomers or fibrils, results in the retraction of neuronal processes, and induction of CCEs in a
concentration dependent manner. Retraction of neuronal processes correlated with the induction
of CCEs and the Aβ monomer or Aβ fibrils showed only minimal effects. In addition, we provide
evidence that induction of neuronal CCEs are autonomous to primary neurons cultured from the
R1.40 mice. Finally, our results also demonstrate that Aβ oligomer treated neurons exhibit elevated
levels of activated Akt and mTOR (mammalian Target Of Rapamycin) and that PI3K, Akt or mTOR
inhibitors blocked Aβ oligomer-induced neuronal CCEs. Taken together, these results
demonstrate that Aβ oligomer-based induction of neuronal CCEs involve the PI3K-Akt-mTOR
pathway.
Background
Alzheimer's disease (AD) is the most common form of
senile dementia and is a leading cause of disability and
death [1,2]. Currently, there are no reliable biomarkers or
therapeutic agents to detect or prevent AD, respectively. A
definitive diagnosis of AD requires the demonstration of
distinctive brain pathology, including extracellular depos-
its of the beta-amyloid (Aβ) peptide in senile plaques and
intracellular aggregates of the microtubule-associated pro-
tein, tau, in neurofibrillary tangles. Another invariant fea-
ture of the disease includes substantial neuronal cell loss
in discrete brain regions, although the mechanisms
underlying the neurodegeneration remain unclear.
Increasing evidences suggest that aberrant neuronal cell
cycle re-entry may precede the regional neurodegenera-
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tion observed in AD. First, several reports have demon-
strated the expression of cell cycle proteins and DNA
synthesis in nerve cells susceptible to death in AD [3-6].
Second, brain tissue from individuals with mild cognitive
impairment (MCI), believed to be the clinical predecessor
to AD [7], reveals the evidence of cell cycle events (CCEs)
even in the absence of substantial AD pathology [3].
Third, neuronal CCEs are observed in a variety of trans-
genic mouse models of AD [3,8]. In particular, we have
observed that the genomic-based amyloid precursor protein
(APP) transgenic mouse model of AD, R1.40, exhibits sig-
nificant re-expression of cell cycle proteins and DNA rep-
lication [9]. The neuronal populations involved and the
timing of the events accurately recapitulate the selective
neuronal vulnerability observed in human AD [3,10].
Finally, we recently reported that neuronal CCEs in the
R1.40 mouse model occur in the absence of Aβ deposition
and yet are dependent upon the amyloidogenic process-
ing of the APP by beta-secretase [9,11]. Together, these
data suggest that APP and its cleavage at the beta-secretase
site play a direct role in the induction of neuronal CCEs.
The exact nature of the neurotoxic substance is still
unknown.
Recently, a number of findings have implicated soluble,
macro- or micromolecular assemblies of Aβ, termed Aβ
oligomers, in the pathogenesis of AD. Small, secreted Aβ
oligomers (dimers and trimers), are capable of inhibiting
long-term potentiation (LTP) in hippocampal slice cul-
tures, an effect blocked by immunoneutralization or inhi-
bition of oligomerization [12-14] and exposure of
primary neurons to synthetic preparations of Aβ oligom-
ers (also referred to as Aβ-derived diffusible ligands,
ADDLs) results in significant synaptotoxicity including
decreased dendritic spine density [15,16] (reviewed in
[17,18]). It has also been reported that the appearance of
a 56 kDa Aβ species (Aβ*56) observed in the Tg2576
mouse model of AD correlates with the timing of memory
impairments in this model. Further, Aβ*56 disrupts mem-
ory when purified and injected into the brains of rats [19].
Finally, our recent studies have demonstrated that crude
Aβ oligomers, but not Aβ monomers, can directly induce
neuronal CCEs in primary cortical neurons [9]. Although
the Aβ oligomers promote diverse biological conse-
quences, the relevant oligomeric species, the biological
mechanisms underlying these effects and the relationship
among the various phenotypic consequences remains to
be determined.
Increasing evidence suggests that the phosphatidylinosi-
tol-3-OH kinase (PI3K)-Akt-mTOR signaling pathway is
directly impacted by Aβ exposure and is altered in AD
brains. First, Aβ oligomers have been shown to modulate
expression and density of insulin receptors that mediate
growth and cell survival through the modulation of PI3K-
Akt pathway [20] (reviewed in [21]). Second, significant
increases in the levels of phosphorylated Akt substrates
such as mTOR (Ser2448) and decreased levels of cell-cycle
inhibitors (p27kip1) are found in AD temporal cortex
when compared to controls [22]. Third, studies in trans-
genic mouse models and patients with AD have docu-
mented alterations in mTOR/p70S6K signaling by Aβ
exposure [23]. Fourth, TOR activation has been demon-
strated to enhance tau-induced neurodegeneration in a
cell-cycle dependent manner in a tauopathy model of Dro-
sophila and that ectopic TOR activation drives cell cycle
and apoptosis in post-mitotic neurons [24]. Finally, the
levels of mTOR and its downstream targets eukaryotic
translation initiation factor 4E binding protein 1 (4E-
BP1), as well as the eukaryotic translation elongation fac-
tor 2 (eEF2) and eEF2 kinases are up regulated in the AD
brain [25]. Together, these studies suggest that the compo-
nents of insulin receptor and PI3K-Akt-mTOR pathway
are affected in AD and correlate with altered cell cycle
related events.
Based on the above studies, we hypothesized that Aβ oli-
gomers alter the PI3K/Akt/mTOR pathway within neu-
rons, and in turn promotes the expression of cell cycle
proteins and the induction of neuronal CCEs. To test this
hypothesis, we exposed primary cortical neurons to size-
exclusion column (SEC) purified monomeric and oligo-
meric samples of the Aβ1–42 peptide. Our results demon-
strate that Aβ oligomers induce neuronal process
retraction and neuronal CCEs in a concentration depend-
ent manner, while the monomeric samples showed no
response. Furthermore, while the presence of CCEs corre-
lated with neuronal process retraction in the cultures,
inhibition of either the PI3K, Akt or mTOR pathway sub-
stantially blocked the neuronal CCEs, while only inhibi-
tion of the PI3K pathway significantly blocked neuronal
process retraction. These studies help identify new com-
ponents of the biological pathways responsible for the
diverse pathological consequences of Aβ oligomers.
Results
Preparation of Aβ monomers and oligomers
To examine the role of specific Aβ species in induction of
neuronal CCEs, we utilized purified synthetic prepara-
tions of Aβ. Aβ oligomers were prepared by established
protocols via disaggregating Aβ peptides in sodium
hydroxide, "aging" of Aβ for various time points in PBS
and finally purification of Aβ monomers and Aβ oligom-
ers via SEC fractionation (Figure 1A and 1B). Aβ prepared
in this manner yielded consistent, homogeneous mono-
mer and oligomer peaks with an increased proportion of
oligomers upon longer incubation times (Figure 1A). As
the 3-hour incubation time yielded relatively equal con-
centrations (peak intensities) of monomeric and oligo-
meric Aβ species without forming protofibrils/fibrils, SECMolecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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fractions from these conditions were utilized for all subse-
quent experiments.
The presence of monomeric and oligomeric Aβ species in
the SEC fractions was confirmed by Western blot analysis.
Consistent with previous findings [26-28], detection with
monoclonal Aβ antibody 6E10 revealed that the mono-
meric preparations contained 4.5 kDa reactive Aβ mono-
mers, while the oligomeric preparations contained both
the larger molecular weight and monomeric Aβ (Figure
1B). Quantification of the relative proportion of the dif-
ferent sized Aβ species in the SEC fractions demonstrated
that the Aβ monomeric fractions contained 100% of Aβ
monomers, while the Aβ oligomeric fractions contained
26% of Aβ monomers, 24% of Aβ dimers, 20% of Aβ trim-
ers, 18% of Aβ tetramers and 12% of higher molecular
weight (> 20 kDa) Aβ oligomers.
Aβ oligomers induce neuronal CCEs
To examine whether SEC purified Aβ monomers and Aβ
oligomers were capable of inducing neuronal CCEs, we
exposed 21 DIV primary cortical neurons to different con-
centrations (0.2 to 4.0 μg/ml) of the SEC fractions for 24
hours in the presence of BrdU. We selected 21 DIV for all
the treatments because majority of neurons at that point
are mature and terminally differentiated. However, we
have consistently observed that ~5–10% of the MAP2 pos-
itive neurons display basal level of BrdU incorporation in
21 DIV cultures (Figure 2M–O Veh). These results are con-
sistent with previous findings on mouse [29,30] and rat
cortical neurons at 5–10 DIV [31]. At present, whether this
baseline induction of BrdU incorporation is due to con-
tinued division of a small number of neuronal stem cells
or accounted for by the de-differentiation of a low
number of non-neuronal cells remains unclear.
Given concerns that the conformation of the Aβ species
could alter during this treatment paradigm, we first exam-
ined the tissue culture media for the sizes of the Aβ species
via Western blot analysis prior to and following exposure
to both Aβ monomers and oligomers. Detection of Aβ
using 6E10 revealed that both monomeric and oligomeric
Aβ species exhibited little alterations in mobility at the 24
hour time point (Figure 1C-24 h) when compared to the
starting material (Figure 1C-0 h) at all of the concentra-
tion ranges examined. These results demonstrate that the
Aβ monomers and oligomers are relatively stable during
the exposure period.
The effect of exposure to Aβ monomer and oligomers on
neuronal CCEs was determined via dual immunofluores-
cence for the neuronal maker MAP2 and BrdU. These
studies revealed an increase in nuclear BrdU incorpora-
tion in Aβ oligomer treated neurons (Figure 2G–I), but
not in Aβ monomer treated neurons (Figure 2D–F), when
compared to vehicle treated neurons (Figure 2A–C).
Quantification of the results indicated a 2- to 5-fold
increase in BrdU incorporation in the Aβ oligomer treat-
ment group (Figure 2N) when compared to the basal level
of BrdU incorporation (13 ± 6%) in vehicle treated groups
(Figure 2M–O – Veh). There was a concentration depend-
ent increase in BrdU incorporation upon exposure of neu-
rons to Aβ oligomers that reached statistical significance at
2.0 to 4.0 μg/ml of oligomers (Figure 2N). By contrast, dif-
ferent concentrations of SEC purified Aβ monomers did
Preparation and characterization of Aβ monomers and Aβ  oligomers Figure 1
Preparation and characterization of Aβ monomers 
and Aβ oligomers. A. Preparation of Aβ monomers and 
Aβ oligomers. Synthetic Aβ peptides were aged for various 
amounts of time in phosphate buffer followed by SEC frac-
tionation, yielding two major peaks corresponding to Aβ oli-
gomers (AβO) and Aβ monomers (AβM), with Aβ oligomers 
eluting at 12–15 min and Aβ monomers eluting at 25–30 min. 
With increased aging, the relative amount of Aβ oligomers 
increased to a maximum at 24 h. The Z-axis is the relative 
absorption intensity at 220 nm. B. Western blot analysis of 
SEC fractionated in vitro preparations of Aβ monomers 
(AβM) and Aβ oligomers (AβO) with the Aβ specific anti-
body 6E10, revealed a single, 4.5 kDa monomeric band for 
AβM and monomer, dimers, trimers, tetramers and large 
molecular weight oligomers that run between 28–90 kDa 
(high 'n' AβOs) for AβO. C, D. Western blot analysis of tis-
sue culture media with 0.2 μg/ml (lanes 1 and 6), 0.4 μg/ml 
(lanes 2 and 7), 0.8 μg/ml (lanes 3 and 8), 2.0 μg/ml (lanes 4 
and 9) and 4.0 μg/ml (lanes 5 and 10) of AβM and AβO at the 
beginning (time = 0 h, C) or end (time = 24 h, D) of the 
experiment revealed a similar migration pattern of AβM and 
AβO at both time points. Asterisk indicates the location of 
abundant proteins in the B27 serum-free supplement.Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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not alter the total number of BrdU positive neurons when
compared to vehicle treated groups at any of the concen-
trations examined (Figure 2D–F and 2M). Interestingly,
the concentration ranges of Aβ oligomers exhibiting
effects on BrdU incorporation in the current studies are
similar to the previously reported effects on synaptotoxic-
ity [15].
To examine whether the effects of oligomeric Aβ on neu-
ronal CCEs could be due to contamination of the purified
oligomeric preparations with extremely low levels of Aβ
fibrils, that were below our limits of biochemical detec-
tion, Aβ fibrils were also prepared [32] and exposed to 21
DIV primary cortical neurons. Exposure of neurons to Aβ
fibrils at a concentration (4.0 μg/ml) at which Aβ oligom-
ers exhibit robust induction of neuronal CCEs, demon-
strates that unlike Aβ oligomers, Aβ fibrils did not induce
any statistically significant alterations in BrdU incorpora-
tion (Figure 2J–L and 2O). Furthermore, we also exam-
ined the effects of exposure to even higher concentration
of Aβ fibrils (20 μg/ml), based on the earlier reports that
Aβ fibrils can induce cell cycle events at higher concentra-
tions [30]. Exposure of neurons to the higher concentra-
tion of Aβ fibrils resulted in a trend towards increased
BrdU incorporation that did not reach statistical signifi-
cance (Figure 2O). Our results are in agreement with ear-
lier reports that ~4.0 μg/ml of Aβ25–35 fibrils did not
induce increased numbers of BrdU positive neurons [29],
while ~40 μg/ml of Aβ1–42  fibrils induced a two-fold
increase in the percentage of neurons incorporating BrdU
[30]. Taken together, these results demonstrate that Aβ
oligomers are a more potent inducer of neuronal cell cycle
events than either Aβ monomers or Aβ fibrils.
To confirm that Aβ oligomer treatment induced aberrant
neuronal CCEs, cell lysates were prepared at different
exposures and examined for induction of the Proliferative
Cellular Nuclear Antigen (PCNA), a marker of the S-phase
Purified Aβ oligomers induce BrdU incorporation in primary neurons Figure 2
Purified Aβ oligomers induce BrdU incorporation in primary neurons. Cultured primary cortical neurons (21 DIV) 
were treated with vehicle (Veh) A-C, 0.4 μg/ml of Aβ monomers (AβM) D-F or 0.4 μg/ml of Aβ oligomers (AβO) G-I or 0.4 
μg/ml Aβ fibrils (AβF) J-L in presence of BrdU for 24 h. Cells were fixed and immunostained with antibodies against MAP2 (A, 
D, G and J) and BrdU (B, E, H and K) demonstrating the induction of BrdU incorporation in MAP2 positive cells (neurons) 
with Aβ preparations, but not with AβM, AβF or vehicle control (merged images in C, F, I and L). Scale bar, 10 μm. M-O 
Quantification of the percentage of BrdU positive/MAP2 positive cells in vehicle, AβM, AβO and AβF treatment groups 
revealed a statistically significant (p = 0.003 for 2.0 μg/ml; p = 0.006 for 4.0 μg/ml; unpaired t test; mean ± SEM; n = 3 independ-
ent experiments) increase in the percentage of BrdU/MAP2 positive cells upon exposure to AβO, but not AβM or AβF, com-
pared to vehicle control. P. Western blot analysis of detergent soluble cell lysates from neurons exposed to different 
concentrations of Aβ with an antibody against the S-phase cell cycle protein, PCNA, and an antibody against the protein load-
ing control, GAPDH. Q. Quantification of the Westernblot for PCNA (relative to GAPDH) revealing a statistically significant 
(p = 0.008 for 20 μg/ml) increase in the PCNA expression in the 20 μg/ml AβO treatment group. PCNA/GAPDH ratio at 20 
μg/ml AβO treatment was assigned as 100%.Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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of cell cycle. Consistent with the results from the quantifi-
cation of BrdU incorporation, treatment with increasing
concentrations of Aβ oligomers induced a concentration-
dependent increase in the levels of PCNA in the soluble
cell lysates from cortical neurons (Figure 2P). Western
blot qauntification of PCNA expression after exposure of
neurons to different concentrations of Aβ oligomers and
normalization to the levels of GAPDH, revealed a concen-
tration dependent increase in the levels of PCNA (Figure
2Q), that reached statistical significance for the highest
concentration of Aβ exposure (41.82 ± 2.9 for vehicle ver-
sus 105 ± 5.0 for 20 μg/ml Aβ oligomer, p = 0.008). By
contrast, exposure to Aβ monomers did not exhibit the
same increase in the levels of PCNA (data not shown).
Taken together, these results demonstrate that purified
preparations of stable Aβ oligomers induce CCEs in pri-
mary cortical neurons in a concentration dependent man-
ner that is not observed with preparations of Aβ
monomers or Aβ fibrils.
Aβ oligomers induce coincident neuronal CCEs and 
dendritic loss
In analyzing the effect of Aβ oligomers on cortical neu-
rons, a decrease in the number of MAP2 staining neuronal
processes was consistently observed (see Figure 2G–I and
Figure 3A–F). In general, control neurons exhibited 4–5
MAP2+ processes per cell, while those exposed to Aβ oli-
gomers exhibited an apparent concentration dependent
decrease in the number of MAP2+ processes together with
increased nuclear BrdU staining. Quantification of these
results was performed by examining the total number of
dendrites per field in 5 random fields per treatment using
a macro ("Dendrites") in the ImagePro Plus™ image anal-
ysis software (Materials and Methods). The data revealed
that the number of dendrites was significantly reduced
upon exposure to increasing concentration of Aβ oligom-
ers (Figure 3H) when compared to either vehicle or
increasing concentrations of Aβ monomer treatment (Fig-
ure 3G) or Aβ fibrils (data not shown). These results are
Aβ oligomers induce loss of MAP2 positive processes in primary neurons coincident with BrdU incorporation Figure 3
Aβ oligomers induce loss of MAP2 positive processes in primary neurons coincident with BrdU incorporation. 
Cultured primary cortical neurons (21 DIV) were treated with vehicle (Veh, A and D), 4 μg/ml Aβ monomers (AβM, B and E) 
or 4 μg/ml Aβ oligomers (AβO, C and F) for 24 hours. Following fixation, cells were immunostained with antibodies against 
MAP2, revealing several long MAP2 positives processes per cell in the vehicle treatment group, a modest reduction in the 
number of MAP2 positive processes in the AβM treatment group and a dramatic reduction in the number and length of the 
MAP2 processes in the AβO treatment group. Scale bar, 10 μm. MAP2 positive neurons with shorter processes displaying 
BrdU incorporation (arrows in F). G-H. Quantification of MAP2 positive dendrites following exposure to Veh or different con-
centrations of AβM (G) and AβO (H) via automated image processing revealed a statistically significant decrease in MAP2 pos-
itive processes (p = 0.006; Veh versus AβO-4 μg/ml; unpaired t test; mean ± SEM; n = 3 independent experiments) when 
compared to either vehicle or AβM. I-J. Quantification of the total number (I) of MAP2 positive processes as well as the 
number of processes longer than 5 μm per cell (J) in both BrdU positive and BrdU negative neurons revealed a statistically sig-
nificant reduction in both number of MAP2 + processes (p = 0.015; mean ± SEM; unpaired t test; n = 3) as well as the number 
of processes longer than 5 μm (p = 0.05; mean ± SEM; unpaired t test; n = 3) in BrdU positive cells when compared to BrdU 
negative cells.Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
Page 6 of 18
(page number not for citation purposes)
consistent with earlier reports demonstrating that Aβ oli-
gomer exposure induced a loss of the spine marker,
drebrin, as well as dramatic changes in spine morphology
and density in mature hippocampal cultures [15]. Similar
findings were obtained upon Aβ exposure of 7 DIV corti-
cal neuronal cultures (data not shown). Interestingly,
none of the Aβ treatments, even at the highest concentra-
tions, altered the total number of MAP2 positive cells nor
exhibited a significant alteration in neuronal cell number
as determined by measuring the formation of formazan
from reduced MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) in an in vitro cell-death
assay (data not shown). These results suggests that con-
sistent with previous data, Aβ oligomer exposure at sub-
nanomolar concentrations induces synaptic and dendrite
loss in the absence of robust neurodegeneration [15,33].
To begin to examine whether the loss of MAP2+ processes
and induction of neuronal CCEs were part of a coordi-
nated response to exposure to Aβ oligomers, we quanti-
fied the number and length of MAP2+ processes in both
BrdU positive and BrdU negative cells exposed to 2.0 μg/
ml Aβ oligomers. Interestingly, there was a 70% reduction
in the total number of MAP2+ processes in BrdU positive
neurons when compared to BrdU negative neurons (Fig-
ure 3F and 3I). In addition, the number of neurons with
MAP2+ processes 5 μm or longer was reduced by 60% in
BrdU positive neurons when compared to BrdU negative
neurons (Figure 3F and 3J). Together, these results dem-
onstrates that the loss of MAP2+ processes is correlated
with the induction of neuronal CCEs and suggests that
both phenotypes are likely part of a coordinated biologi-
cal response of cortical neurons to Aβ oligomer exposure.
Cell-autonomous induction of CCEs and process retraction 
in R1.40 (R/R) neurons
Our results demonstrate that neuronal CCEs and process
retraction can be induced by exposure of wild-type neu-
rons to increasing concentrations of exogenous Aβ oli-
gomers. To examine whether these events are cell
autonomous to neurons in the R1.40 mouse model of
AD, primary embryonic cortical neurons derived from
R1.40 mice (R/R) and wild-type C57BL/6 controls (WT)
were prepared and examined for alterations in basal levels
of neuronal CCEs and the process length.
To examine the baseline levels of neuronal CCEs in the R/
R neurons, BrdU immunofluorescence was performed as
described above. The R/R neurons readily incorporated
BrdU compared to neurons derived from WT controls
(Figure 4A–B). Notably, there was a statistically significant
increase in the number of BrdU positive cells in the R/R
cultures when compared to controls (21.48 ± 1.67 versus
6.8 ± 2.8) (Figure 4C). Similar to our findings of wild-type
neurons exposed to exogenous Aβ oligomers, a majority
of R/R neurons with short MAP2+ processes also incorpo-
rated BrdU. The total number of process in BrdU+ vs
BrdU- neurons was not significantly different, but the
length of the processes in BrdU+ neurons is significantly
shorter than those from BrdU – neurons (data not
shown). A total of approximately 20–25% of the R/R neu-
rons displayed BrdU incorporation, which is statistically
significant and comparable to the levels observed in WT
neurons exposed to 200 nM of exogenous Aβ oligomers
(Figure 2K).
We then quantified the total dendrite count, total number
of processes per cell and total number of processes that are
5 μm or longer from WT and R/R primary neurons. The
data revealed no statistically significant differences in total
dendrite count (Figure 4D) and total number of processes
per neuron (Figure 4E) when compare to WT controls.
However, the number of processes 5 μm or longer were
significantly reduced in R/R neurons compared to control
(0.43 ± 0.06 versus 0.83 ± 0.06) (Figure 4F), suggesting
that majority of R/R neurons have an equal number but
shorter MAP2+ processes when compared to controls.
Together, these results suggest that primary cortical neu-
rons derived from R/R mice exhibit cell autonomous
induction of baseline neuronal CCEs and process retrac-
tion.
Production of Aβ oligomers by R1.40 (R/R) neurons
To determine whether Aβ oligomers are generated in the
primary cortical neurons derived from the R/R mice, LDS
soluble cell lysates from three independent cultures of
non-transgenic WT and R/R neurons were analyzed via
Western blot analysis with the human-specific anti-Aβ
antibody 6E10. Western blot analysis revealed the produc-
tion of human holo-APP in R/R lysates but not in lysates
from WT cultures (Figure 5A). In addition, R/R lysates dis-
played the presence of multiple 6E10 reactive bands
migrating between 14 kDa and 38 kDa that were absent in
WT lysates (arrows, Figure 5A). These bands were also rec-
ognized by an anti-Aβ oligomer specific antibody, NU-1
[34], but were not recognized by antibodies specific to the
N – (22C11) and C-terminus (CT15) of APP (data not
shown).
To further examine whether the neurons from R/R
embryos also secrete Aβ oligomers, immunoprecipitation
analysis on conditioned media from WT and R/R neurons
was performed using antibody 6E10 followed by Western
blot with Aβ oligomer-specific monoclonal antibody NU-
2 [34]. Similar to that observed for neuronal cell lysates,
6E10 immunoprecipitated, NU-2-immunoreactive 14–38
kDa bands were observed in conditioned media from R/R
neurons, but not in WT controls (Figure 5B-R/R). The NU-
2 immunoreactive bands were also discernable in the total
input lysate from R/R but not WT cultures (Figure 5B-
lanes 1 and 4).Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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To further confirm that R/R neurons were generating
higher molecular weight aggregates containing Aβ, we
performed double immunofluorescence on both WT and
R/R neurons with MAP2 and oligomer specific antibodies
NU-1 or NU-2. Notably, the R/R neurons, and not the WT
neurons exhibited NU-1 and NU-2 immunoreactivity
(Figure 5C and 5D). To examine the relative levels of Aβ
generated from the R/R cultures in comparison to the lev-
els of exogenous Aβ oligomers required for induction of
neuronal CCEs, we quantified the levels of both cell asso-
ciated and secreted Aβ (1–40) by ELISA. Notably, the lev-
els of Aβ (1–40) were approximately three orders of
magnitude lower in R/R conditioned media than the low-
est concentration of synthetic Aβ required to significantly
induce neuronal CCEs and process retraction when added
exogenously (2.0 μg/ml versus 2.5 ng/ml; data not
shown). Taken together, our data suggests that R/R neu-
rons generate low levels of cell associated and secreted
high molecular weight aggregates containing Aβ that may
account for the elevated induction of neuronal CCEs and
process retraction observed in these cells.
Alterations in the PI3K-Akt-mTOR pathway following Aβ 
oligomer treatment
There is increasing evidence that the PI3K-Akt-mTOR
pathway is altered upon Aβ stimulation and in human
AD. First, this pathway acts downstream of many cell sur-
face receptors to which Aβ has been demonstrated to
interact with including the alpha 7 nicotinic acetylcholine
receptor (CHRNA7), N-methyl-D-aspartic acid receptors
[35,36] and insulin receptors [20]. Second, in AD cases,
alterations in Akt phosphorylation correlate with the stag-
ing and severity of the disease [37]. These studies, together
with the established role for mTOR as a downstream tar-
get for Akt in regulating growth factor mediated cell sur-
vival and proliferation (reviewed in [38]) suggested that
the PI3K-Akt-mTOR pathway could be responsible for the
induction of neuronal CCEs following Aβ oligomer expo-
sure.
To examine if the exposure of synthetic preparations of Aβ
oligomers to wild-type neurons elevates the levels of pAkt,
we treated primary neurons with increasing concentra-
tions of Aβ monomers and Aβ oligomers and the levels of
pAkt and p-mTOR were determined by In-Cell Western
(ICW) analysis. High-density primary neuronal cultures
were prepared in 96 well plates, exposed to various con-
centrations of Aβ monomers and Aβ oligomers for 24
hours and examined by ICW for pAkt and p-mTOR stain-
ing. Tubulin was utilized as a control for normalization
and values expressed as pAkt/tubulin and p-mTOR/tubu-
lin ratios.
Cell autonomous induction of BrdU and MAP2 process loss  in primary neurons from the R1.40 transgenic mouse model  of AD Figure 4
Cell autonomous induction of BrdU and MAP2 proc-
ess loss in primary neurons from the R1.40 trans-
genic mouse model of AD. Cultured primary cortical 
neurons (21 DIV) from non-transgenic (WT, A) and 
homozygous R1.40 (R/R, B) mouse embryos were incubated 
with fresh NB media in presence of BrdU for 24 h. Following 
fixation, cells were immunostained with antibodies against 
MAP2 (green in A and B) and BrdU (red in A and B) reveal-
ing elevated incorporation of BrdU and a decrease in the 
length of MAP2 positive processes in the R/R cultures. C. 
Quantification of the percentage of BrdU positive/MAP2 pos-
itive cells demonstrated a statistically significant (p = 0.0012; 
unpaired t test; mean ± SEM; n = 4 independent cultures) 
increase in R/R cultures when compared to WT cultures. D-
F. Quantification of the total dendrite count (total area occu-
pied by all MAP2 positive dendrites per a given field/image) 
(D) and number of MAP positive processes per cell (E) were 
not significantly different between WT and R/R cultures, 
while the number of MAP2 positive processes longer than 5 
μm per cell (F) were significantly (p < 0.001; unpaired t test; 
n = 4 independent cultures) reduced in the R/R cultures 
when compared to the WT cultures.Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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Presence of cell-associated and secreted oligomeric Aβ assemblies in primary neurons from the R1.40 transgenic mouse model  of AD Figure 5
Presence of cell-associated and secreted oligomeric Aβ assemblies in primary neurons from the R1.40 trans-
genic mouse model of AD. A. Western blot analysis of detergent soluble cell extracts of from cultured primary cortical 
neurons (21 DIV) from non-transgenic (WT) and homozygous R1.40 (R/R) mice revealed the presence of numerous bands 
migrating between 14 and 38 kDa (arrows) that were immunoreactive with antibody 6E10 (recognizing residues 1–17 of Aβ1–
42 peptide) in the R/R samples but not WT samples. Each lane for WT and R/R cultures represents extracts from three inde-
pendent cultures. hAPP = holo APP; βCTF = β C-terminal fragment. Asterisk denotes the presence of non-specific bands 
detected with the human-specific 6E10 antibody. B. Primary cortical neurons (21 DIV) from WT and R/R mice were prepared 
and grown for 24 h in the presence of fresh NB media with (+) or without (-) the B27 serum supplement. Immunoprecipitata-
tion of conditioned media with antibody 6E10, followed by Western blot analysis with the anti-Aβ oligomer specific antibody, 
NU-2 revealed the presence of multiple NU-2 reactive bands between 30–40 kDa (arrows) that were present in the R/R (lanes 
5 and 6), but not WT (lanes 2 and 3) samples. Lanes 1 and 4 shows total input lysates. C-D. Aβ oligomers are secreted by R/R 
neurons. Cultured primary cortical neurons (21 DIV) from wild-type (WT) and homozygous R1.40 (R/R) embryos were dou-
ble labeled with MAP2 (green in C and D) or Aβ oligomer specific antibodies NU-1 (red in C) or NU-2 (red in D). Merged 
images are shown in right panel. NU-1 and NU-2 immunreactivities were specifically observed in R/R, but not WT, neurons. 
Scale bar 30 μm.Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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The data demonstrates that the relative levels of pAkt were
elevated upon exposure to increasing concentration of Aβ
oligomers, but not Aβ monomers (Figure 6A and 6C).
Neurons exposed to Aβ oligomers at a concentration of
2.0 μg/ml exhibited a statistically significant increase in
pAkt levels that further increased to an approximately
five-fold induction of pAkt upon exposure to 20.0 μg/ml
of Aβ oligomers (Figure 4C). By contrast, exposure to Aβ
monomers did not result in significantly altered levels of
pAkt at any of the concentrations examined (Figure 6A
and 6C). Notably, the concentration dependence of pAkt
levels in response to Aβ oligomer treatment was similar to
that observed for induction of neuronal CCEs (Figure
2N).
The levels of p-mTOR also increased upon exposure to Aβ
oligomers. However, unlike pAkt levels, exposure of neu-
rons to increasing concentrations of Aβ oligomers resulted
in a bell-shaped curve, with statistically significant
increase in p-mTOR at the 3.0 μg/ml concentrations
(0.028 ± 0.0025 for AβM vs 0.0429 ± 0.008 for AβO) (Fig-
ure 6B and 6D) that dropped to basal levels upon expo-
sure to higher concentrations of Aβ oligomers (4.0, 10.0
and 20 μg/ml). Meanwhile, exposure of neurons to Aβ
monomers did not alter p-mTOR levels. The activation
patterns of phospho-Akt and phospho-mTOR measured
by ICW following Aβ treatments are consistent with ear-
lier reports on the effect of Aβ1–42 on the activation of PI3K
pathway [39,23]. Wei et al., (2002) have observed that
treatment of SH-SY5Y cells with 4 μM (equivalent of 15
μg/ml) of aggregated Aβ1–42 activated Akt and this activa-
tion was sustained over 24 h period [39]. Similarly, Lafay-
Chebassier et al., (2005) have observed aggregated Aβ1–42
at a high concentration (20 μM or equivalent of 80 μg/
ml)) down-regulated the p-mTOR levels in differentiated
Neuro-2a cells [23]. Together these results suggest that
molecular components of PI3K pathway are sensitive to
Aβ treatment.
To confirm the ICW analysis of pAkt levels, conventional
Western blot analysis was performed on cell lysates of
neurons exposed to 2.0 μg/ml of Aβ oligomers, a concen-
tration that was sufficient for the induction of neuronal
CCEs. Western blots were probed with antibodies against
pAkt (Ser 473) and total Akt and quantified for the rela-
tive levels of pAkt/Akt (Figure 7A and 7B). Our results
demonstrate a relatively modest, but statistically signifi-
cant increase in the pAkt/Akt ratio upon exposure to 2.0
μg/ml Aβ oligomers, with a 13% increase in the pAkt/Akt
ratio following Aβ oligomers treatment compared to vehi-
cle (0.6 ± 0.0096 vs 0.504 ± 0.009) and a 23% increase
when compared to Aβ monomer treatment (0.6 ± 0.0096
vs 0.44 ± 0.014). These results confirm our ICW results
and together demonstrate that exposure of neurons to Aβ
oligomers results in altered pAkt and p-mTOR levels that
correlate with the presence of neuronal CCEs as well as
MAP2+ process loss.
To determine whether the downstream effectors of mTOR
activation were also altered upon Aβ oligomer treatment,
the levels of translation inhibitor 4E-BP1(inhibited by
mTOR mediated phosphorylation) were examined fol-
lowing Aβ oligomer treatment at a concentration of 2.0
μg/ml. Our results demonstrate a statistically significant,
30–50% increase in the p4E-BP1S65/GAPDH ratio upon
exposure to 2.0 μg/ml Aβ oligomers compared to vehicle
or Aβ monomer exposure (Figure 7A and 7C), suggesting
alterations in the downstream targets within mTOR path-
way by Aβ oligomers.
Alterations in the PI3K-Akt-mTOR pathway in R1.40 (R/R) 
neurons
To examine whether R/R neurons, which exhibit elevated
levels of neuronal CCEs and also secrete Aβ oligomers,
also display alterations in PI3K-Akt-mTOR pathway, the
levels of pAkt and p-mTOR in WT and R1.40 neuronal
lysates was determined. Western blot analysis with an
antibody against pAkt revealed significantly elevated lev-
els of pAkt in R/R samples when compared to WT samples
(0.1355 ± 0.007 versus 0.225 ± 0.04 for WT and R/R
respectively) (Figure 7D and 7E). On the other hand,
Western blot analysis with antibodies against p-mTOR did
not reveal any significant differences in the levels of p-
mTOR/GAPDH between WT and R/R (Figure 7D and 7F).
These results suggest that R/R neurons, which produce
endogenous oligomeric Aβ species and exhibit elevated
CCEs, also exhibit alterations in the Akt pathway.
PI3K, Akt and mTOR inhibition prevents Aβ oligomer-
induced neuronal CCEs
To provide evidence that the PI3K-Akt-mTOR pathway is
directly involved in the Aβ oligomer-induced neuronal
CCEs, WT primary cortical neurons were incubated with
specific, cell-permeable, irreversible pharmacological
inhibitors (Wortmannin for PI3K, Akt-inhibitor for Akt
and Rapamycin for mTOR) 30 min prior to addition of Aβ
oligomers (2.0 μg/ml) in the presence of BrdU. The
number of BrdU+ MAP2+ cells was quantified for each
treatment group in triplicates. Strikingly, pre-treatment of
primary cortical neurons with PI3K, Akt or mTOR inhibi-
tors resulted in over 80% reduction in the number of
BrdU positive neurons compared to Aβ oligomer exposure
alone (Figure 8A). This decrease in BrdU incorporation
was not merely due to fewer numbers of cells as indicated
by similar numbers of MAP2+ cells and DAPI stained
nuclei and also the inhibitors alone did not have any
direct effect on BrdU incorporation (data not shown).
This suggests that the inhibition of several steps within the
PI3K/Akt/mTOR pathway blocks Aβ oligomer induced
neuronal CCEs.Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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Inhibition of PI3K prevents Aβ oligomer-induced neuronal 
process loss
Exposure of primary neurons to Aβ oligomers results in
neuronal CCEs that are correlated with loss of neuronal
processes (Figure 3). To examine whether the PI3K/Akt/
mTOR pathway is involved in the Aβ oligomer-induced
neuronal process loss, the total number of MAP2+ proc-
esses was quantified in presence or absence of the wort-
mannin, Akt inhibitor and rapamycin. Unlike the results
obtained for induction of neuronal CCEs, only the PI3K
inhibitor significantly rescued the Aβ oligomer-induced
neuronal process loss. A 76% percent rescue in the total
dendrite count (14.79 ± 1.89 for AβO versus 64.5 ± 6.67
for AβO+wortmannin) was observed with wortmannin.
While the Akt inhibitor and rapamycin were indistin-
guishable from Aβ oligomer treated cultures (Figure 8B).
Aβ oligomer treatment increases the levels of pAkt and p-mTOR in primary neurons Figure 6
Aβ oligomer treatment increases the levels of pAkt and p-mTOR in primary neurons. A. Cultured primary corti-
cal neurons (21 DIV) plated in 96-well plates were treated with either vehicle (Veh) or increasing concentrations (0.4, 2.0, 3.0, 
4.0, 10 and 20 μg/ml) of either Aβ monomer (AβM) or Aβ oligomer (AβO) for 24 h. Following fixation, In-Cell Western anal-
ysis, using primary antibodies against tubulin and phosphorylated-Akt (pAktS473) followed by infrared-conjugated secondary 
antibodies, revealed an apparent increase in pAkt levels in AβO treated cultures. C. Quantification of the pAkt/Tubulin ratio in 
these cultures revealed a dose-dependent statistically significant increase in AβO treated cultures at AβO concentrations 
above 2.0 μg/ml (2.0 μg/ml-p = 0.006; 3.0 μg/ml -p = 0.04; 4.0 μg/ml -p = 0.005; 10 μg/ml -p = 0.008; 20.0 μg/ml -p = 0.01; mean 
± SD; n = 4; unpaired t test), while exposure to AβM did not reveal any alterations in the pAkt/Tubulin ratio. All comparisons 
were made against AβM at respective concentrations. B. In-Cell Western analysis with primary antibodies against tubulin and 
phosphorylated-mTOR (p-mTORS2448) revealed an apparent increase in the levels of p-mTOR in the middle concentration 
ranges (2.0 – 4.0 μg/ml). D. Quantification of the p-mTOR/tubulin ratios revealed a statistically significant (3.0 μg/ml -p = 0.04; 
unpaired t test; mean ± SD; n = 4) increase in AβO exposed cultures when compared to AβM exposed cultures at similar con-
centrations. At elevated concentrations of AβO (> 4.0 μg/ml), there was no significant increase in the p-mTOR/tubulin ratio. 
'X' denotes wells with no cells (in panel A and B).Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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Together, these results suggest that neuronal CCEs and
neuronal process loss are part of a coordinated cellular
response to Aβ oligomers that involves the common
upstream PI3K pathway, while neuronal CCEs, but not
neuronal process loss acts via the downstream Akt and
mTOR pathway.
Discussion
The current studies offer significant insights into the
mechanisms underlying the induction of neuronal cell
cycle abnormalities observed in human AD. Neuronal
CCEs are an early and robust marker for neurons subject
to degeneration in AD. Although aberrant neuronal cell
cycle is closely linked to AD pathogenesis [3-6], the cellu-
lar/molecular mechanisms responsible for the induction
of neuronal CCEs remains unclear. Recent findings from
our laboratory has demonstrated the induction of neuro-
nal CCEs in the genomic-based R1.40 mouse model of AD
that occurs substantially prior to Aβ deposition, correlate
with the relative levels of Aβ generated, dependent upon
Elevation of pAkt levels in primary neurons treated with Aβ oligomers and in neurons from the R1.40 transgenic mouse model  of AD Figure 7
Elevation of pAkt levels in primary neurons treated with Aβ oligomers and in neurons from the R1.40 trans-
genic mouse model of AD. A. Cultured primary cortical neurons (21 DIV) were treated with vehicle (Veh), 2.0 μg/ml Aβ 
monomers (AβM) or 2.0 μg/ml Aβ oligomers (AβO) for 24 hours. Western blot analysis of cell extracts with antibodies against 
pAktS473, total Akt, p4E-BP1S65 and GAPDH revealed a slight increase in the levels of pAkt and p4E-BP1 in AβO treated cul-
tures when compared to vehicle or AβM treated cultures. B-C. Quantification of the ratios of pAkt/total Akt (B) and p4E-BP1/
GAPDH (C) revealed statistically significant increases upon exposure to AβO (2.0 μg/ml) when compared to AβM treatment 
(2.0 μg/ml) or vehicle controls (p < 0.05 for AβO versus vehicle or AβM; unpaired t test; mean ± SEM; n = 3 independent 
treatments). D. Western blot analysis of detergent soluble cell extracts of from cultured primary cortical neurons (21 DIV) 
from non-transgenic (WT) and homozygous R1.40 (R/R) mice with antibodies against pAkt (pAktS473), p-mTOR (p-mTORS2448) 
and GAPDH revealed elevated levels of pAkt (pAktS473) but not p-mTOR in the R/R neurons when compared to WT neurons. 
E-F Quantification of the ratios of pAkt/GAPDH (E) and p-mTOR/GAPDH (F) revealed statistically significant increases in the 
levels of pAkt/GAPDH (p = 0.04; unpaired t test; mean ± SEM; n = 3 independent cultures) but not p-mTOR/GAPDH (p = 
0.74; unpaired t test; mean ± SEM; n = 3 independent cultures) in cell lysates form the R/R cultures.Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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Aβ oligomer induced neuronal CCEs are blocked with inhibitors of the PI3K/Akt/mTOR pathway Figure 8
Aβ oligomer induced neuronal CCEs are blocked with inhibitors of the PI3K/Akt/mTOR pathway. A. Cultured 
primary cortical neurons (21 DIV) were pretreated for 30 min with the PI3K inhibitor wortmannin (100 nM), an Akt inhibitor 
(100 nM) and the mTOR inhibitor rapamycin (1 μM), followed by exposure to 2.0 μg/ml of Aβ oligomers (AβO) for 24 hours 
in the presence of BrdU. Following fixation, cells were stained with specific antibodies against BrdU and MAP2. Quantification 
of the BrdU positive/MAP2 positive cells demonstrated a statistically significant decrease in the percentage of neurons positive 
for BrdU with all three inhibitors (p < 0.001 for AβO vs AβO+wortmannin, AβO+Akt inhibitor and AβO+rapamycin; one-way 
ANOVA with Tukey multiple comparison test for pair-wise comparisons; mean ± SEM; n = 4 independent treatments per 
group). B. Quantification of the loss of MAP2 positive processes upon treatment with AβO in the presence of the PI3K, Akt 
and mTOR inhibitors was determined via automated image processing and revealed a statistically significant increase in the 
number of MAP2 positive processes upon pre-treatment with the PI3K inhibitor (p = 0.0005; unpaired t test; mean ± SEM; n = 
4 independent treatments), but not the Akt or mTOR inhibitors when compared to AβO treatment alone. C. Diagram outlin-
ing a potential pathway underlining the effects of Aβ oligomers on neuronal process retraction and CCEs. Our data suggest 
that Aβ oligomers activate the PI3K-Akt-mTOR signaling pathway. Activation of PI3K causes phosphorylation of Akt at Ser473, 
which in turn activates mTOR via phosphorylation at Ser2448. Activation of mTOR results in induction of cell proliferation by 
down regulation of 4E-BP1 via inhibitory phosphorylation at ser65. Interestingly, our data suggest that the dendritic alterations 
induced by Aβ oligomers is blocked via inhibition of PI3K via as yet to be identified downstream effectors.Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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the amyloidogenic processing of APP and can be induced
in primary neurons with crude preparations of Aβ oligom-
ers [9]. The studies described here provide a further con-
firmation of the role of Aβ oligomers in the induction of
neuronal CCEs as well as neuronal process retraction and
implicates the role of the PI3K/Akt/mTOR signaling path-
way in the specific induction of neuronal CCEs.
The current findings utilized relatively pure preparations
of Aβ monomers and Aβ oligomers. The crude prepara-
tions of Aβ that we used in our earlier studies was based
on an established protocol [32], with which we and others
have observed different biological effects on neuronal
CCEs [9], synapse and dendrite integrity [15], inhibition
of LTP [12] and neuronal viability [32]. However, the Aβ
monomers prepared via these protocols inevitably con-
tains low-n Aβ oligomers (trimers and tetramers), which
confounds the interpretation regarding the specific effects
of Aβ oligomers on neurons. To overcome this, the current
studies prepared mixtures of synthetic Aβ monomer and
oligomers via aging of the samples for 24 hours and sub-
sequently fractioning the sample into Aβ monomers and
oligomers using size exclusion chromatography. Indeed,
SEC fractionation yielded two distinct peaks for Aβ oli-
gomers and Aβ monomers which when separated by SDS-
PAGE yielded a single distinct band at 4.5 kDa for purified
Aβ monomers and multiple oligomeric as well as a mon-
omeric Aβ bands for the purified Aβ oligomers. These
results are entirely consistent with previous studies exam-
ining the preparation and purification of synthetic Aβ spe-
cies via SEC and SDS-PAGE, in which SDS-PAGE appears
to alter the migration pattern of the Aβ species [26-28].
Another significant issue regarding the postulated biolog-
ical effects of Aβ monomers and oligomers concerns the
potential for induction of altered Aβ species during the
experimental paradigm. In the current experiments, a
detailed analysis of the Aβ monomers and oligomers from
the media of the cells via SDS-PAGE revealed no signifi-
cant alterations in the migration pattern of the Aβ mono-
mers and oligomers during the 24 hour incubation
utilized in the current studies.
These studies confirmed that SEC purified Aβ oligomers,
and not similar concentrations of SEC purified Aβ mono-
mers or preparations of Aβ fibrils were capable of induc-
ing neuronal CCEs in a concentration-dependent manner.
Quantification of BrdU incorporation in these cultures,
revealed that neurons treated with 4.0 μg/ml of Aβ oli-
gomers exhibited ~40% of the neurons incorporating
BrdU compared to ~5–10% for the Aβ monomers, Aβ
fibrils or vehicle control. In addition to increased BrdU
incorporation these studies also confirmed increased
expression of the S-phase cell cycle protein PCNA.
While several previous studies have suggested that fibrillar
Aβ can directly induce CCEs [29,30,40], these experi-
ments were performed in differentiated SHSY5Y cells
[29,40], the concentration of Aβ utilized to induce CCEs
was in the μM range [30] (versus effects observed with as
little as 2.0 μg/ml or equivalent of 500 nM in the present
study) with longer incubation times (previous studies uti-
lized 72 hour exposure versus 24 hour exposure in the
present study) [30]. Moreover, in the earlier reports the Aβ
preparations were likely crude mixtures of monomers, oli-
gomers and fibrils (versus the SEC purified preparations
in the present study). Numerous other studies have also
documented biological effects of Aβ oligomers in the nM
(< 4.0 μg/ml) range (similar to those used in the present
study) including synaptic loss [15], inhibition of LTP [12]
and impairment of memory in animal models of AD [19].
These studies suggest that Aβ oligomerization can induce
biological effects in certain neuronal populations, includ-
ing expression of certain cell cycle proteins, DNA replica-
tion as well as alterations in dendritic/synaptic structures
and general morphology.
Our results demonstrate that purified Aβ oligomers
induce both dendritic loss and CCEs within the same
groups of neurons. Intriguingly, several recent studies
have demonstrated that Aβ oligomers can directly cause
loss of synaptic proteins such as drebrin, PSD95, altera-
tions in several neurotransmitter receptors including,
nAChRs [41]; muscarinic receptors [42] and glutamate
receptor trafficking [43], altered spine composition, mor-
phology and density [15], as well as dendritic pathology
[44] both in vivo and in vitro. Taken together with the
results presented here, this supports the hypothesis that
Aβ oligomers induce a common biological response that
involves both dendrite loss and induction of neuronal
CCEs.
We also demonstrated that the induction of CCEs is cell
autonomous to primary cortical neurons from the R1.40
(R/R) mouse model, and is accompanied by the shorten-
ing of dendritic processes, In addition, we detected the
presence of 17 to 38 kDa Aβ-containing oligomers in the
R/R neurons, but not in control cultures. Notably, the lev-
els of Aβ in the R/R neuronal cultures (2.5 ng/ml) is sub-
stantially less than that utilized to induce neuronal CCEs
in wild-type neuronal cultures (2 μg/ml). However, as
APP is expressed under the control of the human APP pro-
moter in the R/R neurons and expressed from early
embryonic stages [45,46], the R/R neurons will be chron-
ically exposed to low-levels of Aβ species, as opposed to
the acute 24 hour exposure of the 21 DIV wild-type neu-
rons. In support of this idea, R/R neurons exhibit shorter
neuronal processes even at earlier DIV (data not shown).Molecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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It should be noted that the induction of neuronal CCEs in
the R/R neuronal cultures could be due to the elevated
expression of human APP and its processed products,
some of which have been demonstrated to participate in
cellular adhesion and/or neuronal differentiation
(reviewed in [47]). Future experiments will be required in
order to determine whether the production of Aβ species
in R/R neurons is directly responsible for the induction of
CCEs and dendrite shortening, including the use of β- and
γ-secretase inhibitors as well as R/R neurons lacking β-
secretase.
While the precise molecular mechanisms underlying Aβ
oligomer-driven induction of neuronal CCEs and den-
drite loss is not completely clear, our data support a
potential role of the PI3K/Akt/mTOR pathway. First,
exposure of primary neurons to increasing concentrations
of Aβ oligomers, but not Aβ monomers, resulted in
increased levels of p-AktS473. This is consistent with the
earlier reports on ADDL induced phosphorylation of Akt
at ser473 is associated with removal of dendritic insulin
receptors and synaptotoxicity [20]. Second, exposure of
primary neurons to Aβ oligomers also elevated levels of
phospho-mTORs2448  and phospho-4E-BP1s65, down-
stream targets of Akt. While other reports have suggested
either unaltered [48] or decreased [23] phospho-mTOR
levels in APPSL/PSI KI mouse models of AD and following
Aβ treatment in N2a cell lines respectively, an increase in
mTOR phosphorylation has been reported in the AD
brain [22,25]. The discrepancy between increased phos-
pho-mTOR levels in our study and reduced phospho-
mTOR levels in Aβ treated N2a cells [23] may be due to
different preparations of Aβ peptide used (oligomeric Aβ
at < 4.0 μg/ml or in 1000 nM concentration-our study;
versus fibrillar Aβ at 20 μM or equivalent of 80 μg/ml -
[23]). Finally, direct evidence for the participation of the
PI3K/Akt/mTOR pathway in the induction of neuronal
CCEs upon Aβ oligomer exposure was provided by dem-
onstration that inhibition of either any one component of
this pathway significantly inhibited BrdU incorporation.
Interestingly, earlier reports, using pharmacological and
genetic means, have demonstrated that PI3K/Akt does
play a crucial role in the proliferation of neural progenitor
cells by transducing intracellular signals from multiple
mitogens including fibroblast growth factor-2, sonic
hedgehog, and insulin-like growth factor [49,50]. In addi-
tion, inhibition of mTOR in cancerous tissue has been
shown to decrease cell proliferation (reviewed in [51]).
In summary, our results demonstrate that purified Aβ oli-
gomers, but not Aβ monomers or fibrils, induce neuronal
CCEs by altering components of the PI3K/Akt/mTOR
pathway (Figure 8C). Further studies are required to
examine the detailed molecular mechanisms underlying
the various biological effects of Aβ oligomers and relate
this to specific biochemical and pathological alterations
that occur in AD. Significantly, there are several compo-
nents of the PI3K/Akt/mTOR pathway that can be
approached therapeutically to test the significance of neu-
ronal CCEs in mouse models as well as in human AD.
Materials and methods
Antibodies
For immunocytochemistry
a mouse monoclonal antibody against microtubule-asso-
ciated protein 2 (1:1000; MAP2; Sigma, St. Louis, MO)
and a rat monoclonal antibody against BrdU (1:1000;
Abcam, Cambridge, MA), mouse monoclonal antibodies
against Aβ oligomers/ADDLs (NU-1 or NU-2; 1:100) were
utilized [34].
For western immunoblots
a mouse monoclonal antibody against Aβ oligomers/
ADDLs (NU-2; 1:2000) [34], a mouse monoclonal anti-
body against human Aβ (6E10; 1:5000; #SIG-39320; Cov-
ance, USA) a rabbit polyclonal antibody against phospho-
AktSer473 (1:1000; #9271, Cell Signaling, Danvers, MA), a
rabbit polyclonal against total Akt (1:1000; #9272, Cell
Signaling, Danvers, MA) a rabbit monoclonal antibody
against phospho-mTORSer2448 (1:200; clone 49F9, #2976,
Cell Signaling, Danvers, MA), a rabbit polyclonal anti-
body against phospho-4E-BP1S65  (1:1000; #9451; Cell
Signaling, Danvers, MA), a mouse monoclonal antibody
against PCNA (1:1000; #SC-56, Santa Cruz Biotechnolo-
gies, Santa Cruz, CA), a mouse monoclonal antibody
against GAPDH (1:20,000; #MAB374; Millipore Corpora-
tion, USA) and a rabbit polyclonal antibody against tubu-
lin (1:200; #T3526; Sigma, St. Louis, MO) were utilized.
For in-cell westerns
A rabbit polyclonal antibody against phospho-AktSer473
(1:100), a rabbit monoclonal antibody against phospho-
mTORSer2448  (1:200), a mouse monoclonal antibody
against tubulin (1:200; DM1A, NeoMarkers, Fremont,
CA) or rabbit polyclonal antibody against tubulin (1:200;
T3526; Sigma, St. Louis, MO) were utilized.
In vitro preparation of Aβ1–42 monomeric and oligomeric 
samples
The method for preparations and purification of mono-
meric and oligomeric Aβ1–42 was based on Walsh et al.,
(1997) with minor modifications [52]. Briefly, synthetic
Aβ1–42 peptide was prepared using standard fluorenyl-
methyloxycarbonyl chloride chemistry on an automated
433A synthesizer (Applied Biosystems), and was purified
by HPLC using a Hamilton PRP-3 preparative column.
The purified peptide was characterized by mass spectrom-
etry and nuclear magnetic resonance spectroscopy [53]. A
stock solution of monomeric peptide was prepared in 10
mM sodium hydroxide solution (pH 10.5), from whichMolecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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aliquots were removed and diluted into cold (0–5°C)
sodium phosphate buffer at pH 7.4. The pH was main-
tained at 7.4 using cold dilute sodium hydroxide or trif-
luoroacetic acid solutions. The sample was allowed to age
at room temperature, during which aggregation occurred,
and the extent of aggregation was monitored by size exclu-
sion chromatography (SEC) using a Sephadex™ G-75 size
exclusion column at a flow rate of 0.5 ml/min. The col-
umn was equilibrated with 10 mM sodium phosphate
buffer pH 7.4, which was filtered and degassed to elimi-
nate any particulates or gas that may be present. Mono-
meric and oligomeric fractions were collected and kept
cold (0–5°C) until needed for testing on cells. The oli-
gomer sample eluted first (12–15 min), whereas the mon-
omer eluted as a second band (25–30 min). In this
modified method, Aβ fibrils are excluded from the Sepha-
dex G-75 column since they have molecular mass in
excess of 100 kDa, which is the exclusion limit of the col-
umn. Therefore, Aβ fibrils are not present in our SEC
monomeric or SEC oligomeric samples as previously
reported [52]. In addition, we confirmed the absence of
Aβ1–42 fibrils in our SEC samples by SDS-PAGE analysis
(Figure 1B).
The Aβ1–42 concentration of the eluted fractions was deter-
mined using Beers law (A = εLc,) where A is the absorb-
ance measured for the sample at 220 nm, and e is the
extinction coefficient expressed as 50,000 M-1cm-1 at 220
nm [54]. The extinction coefficient was determined at
214-, 220-, and 280-nm [55].
The preparation of synthetic Aβ1–42 fibrils was prepared
based on the published protocol with minor modification
[32]. Briefly, HFIP-treated lyophilized Aβ1–42 peptide (A-
1163-1; rPeptide, Bogart, GA) was carefully and com-
pletely resuspended to 5 mM in 1% ammonium hydrox-
ide (Sigma, St. Louis, MO) by pipette mixing followed by
brief sonication. 5 mM samples were aliquoted and stored
at -20°C until further use. The recombinant Aβ1–42 pep-
tide was diluted to 100 μM (40 μg/ml) in 100 mM HCl
and incubated at 37°C for 24 h to obtain Aβ1–42 fibrils.
Fibrils were diluted in Neurobasal media prior to cell
treatment.
Primary cortical neuronal cultures and Aβ treatments
Embryonic cortical neurons (E16.5 C57BL/6 mouse
embryos) from wild type-(WT) or homozygous R1.40
transgenics (R/R) were isolated by standard procedures
[56]. Briefly, embryos were collected in ice-cold PBS glu-
cose, and the cortical lobes dissected. The meninges were
subsequently removed, and the cortices placed in 1×
trypsin-EDTA and DNAse (1.6 units/embryo) for 15 min
at 37°C. The tissue was removed from the trypsin solution
and placed in DMEM with 10% fetal bovine serum to
inactivate the trypsin, followed by transfer to Neurobasal
media supplemented with B-27, penicillin-streptomycin
(1×), and L-glutamine (0.3 mM) (NB-media). Tissue was
triturated (10 times) through a 5 ml pipette and allowed
to settle to the bottom of a 15 ml conical tube. Cells in the
solution were removed and plated onto poly-L-lysine-
coated glass coverslips (0.05 mg/ml) at a density of
40,000 cells/well in 24-well plates or 160,000 cells in 6-
well plate. All cultures were grown for 21 days in vitro
(DIV) before any treatment.
To assess the effect of monomeric and oligomeric Aβ1–42
on neuronal CCEs, the SEC fractions or the phosphate
buffer (PB) as vehicle (control) were diluted serially in
NB-media containing 10 μM BrdU and exposed to the
neurons for 24 h. For the analysis of specific inhibitors, 21
DIV cortical neurons were pre-incubated for 30 min with
following inhibitors; wortmannin (PI3K inhibitor,
W1628, Sigma; final concentration of 100 nM)[57], Akt
inhibitor (A6730, Sigma; final concentration of 1
μM)[58] or rapamycin (mTOR inhibitor, final concentra-
tion of 100 nM)[59] in presence or absence of 10 μM
BrdU. The neurons were subsequently treated with Aβ oli-
gomers (500 nM) for 24 h. To study the basal levels of
neuronal CCEs in neurons from R1.40 mouse embryos,
on 20 DIV, NB media was replaced with fresh NB-media
containing 10 μM BrdU and incubated for 24 h. Cells were
fixed with 4% paraformaldehyde in PB at room tempera-
ture for 30 min, washed and stored in phosphate buffered
saline (PBS). All experiments were performed in tripli-
cates and on cultures from three different litters.
Immunocytochemistry
For visualization of BrdU incorporation, cells were treated
with 2 N HCl for 30 min at 37°C, neutralized in 0.1 M
sodium borate (pH 8.6) for 10 min and washed exten-
sively in PBS (5 times). Cells were blocked with 5% nor-
mal goat serum in PBS with 0.4% Triton X-100 for 1 h at
room temperature, incubated overnight at 4°C with the
primary antibodies (in blocking buffer) against MAP2 and
BrdU. Following 3 washes with PBS at room temperature
(RT), cells were incubated with anti-mouse and anti-rat
secondary antibodies conjugated to Alexa400 and
Alexa546 (1:1000; Invitrogen, Eugene, OR) for 1 h at RT.
Cells were subsequently washed with PBS and cover-
slipped with hard-set mounting media with DAPI (Vector
Laboratories, Burlingame, CA).
Quantification of cells positive for MAP2 and BrdU
The number of cells positive for BrdU only, MAP2 only or
positive for both were quantified by scoring five random
fields per treatment per each concentration on digital
images obtained on a fluorescent microscope. By assign-
ing total number of MAP2 positive cells per treatment as
100%, the percentage of total number of MAP2 positive
and BrdU positive cells were calculated, normalized andMolecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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expressed as mean ± SEM (n = 3). To quantify the percent-
age of MAP2 positive neurites per cell per treatment, the
digital images was processed using the Image Pro Plus
software package (Media Cybernetics, Bethesda, MD).
First, the images were skeletonized with in-built morpho-
logical filter – "Thinning". This algorithm converts all
MAP2 positive processes to 1-pixel thick open branches
for accurate quantification. Thinned MAP2 positive phot-
omicrographs were further processed with a specific
Image Pro Plus macro ("Dendrites") that specifically
quantifies the total number and the area of MAP2 positive
processes per cell in each field. A dendrite, as defined by
the Image Pro software, is a one pixel wide process off of
a larger (two or more pixels wide) object (surface of the
cell body). The "Dendrite" macro creates a mask on all the
dendrites originating from different objects (cell body) in
a visual field and quantifies total area occupied by the
masked one pixel wide dendrites. The mean ± SEM (n = 3)
of MAP2 positive neurites from five different fields per
treatment were quantified and the percentage difference
was determined by comparing with vehicle treated group
that was assigned 100%. Data were statistically analyzed
by an unpaired t test (GraphPad Prism, GraphPad Soft-
ware Inc. San Diego, CA).
Quantification of the total number and length of MAP2 
positive processes per neuron
The total number of dendrites per MAP2 positive neuron
and the mean dendritic length of 5 μm or more per BrdU
positive and BrdU negative neurons were analyzed as
above except that after "thinning" the images, the den-
dritic segments originating from one neuron and the total
number of dendrites measuring 5 μm or more in length
were manually quantified. At least, 5 visual fields per
treatment were quantified and expressed as mean ± SEM.
Each treatment was done in triplicates in three independ-
ent experiments. Data were statistically analyzed by an
unpaired t test (GraphPad Prism).
Immunoprecipitation
Immunoprecipitations from neuronal conditioned media
was performed using a modified protocol of Sarkar et al.,
2008 [60]. Briefly, 21 DIV conditioned media (CM)
grown with or without B27 serum supplement for 24 h
was collected, centrifuged at 1000 × g for 10 min to
remove dead cells and then mixed with protease inhibitor
cocktail (1:1000; Sigma Aldrich, St. Louis, MO). CM was
concentrated via an Ultracel YM-10 (10,000 MWCO, Mil-
lipore, Bedford, MA) centricon filter column centrifuged
at 3000 × g for 15 min at 4°C. CM was subsequently pre-
cleared by incubating with pre-blocked 10% protein-A-
sepharose beads (GE Healthcare) for 1 h at 4°C. Aβ was
immunoprecipitated by incubating pre-cleared CM with
human specific monoclonal antibody 6E10 overnight at
4°C, then they were incubated with pre-blocked 10% Pro-
tein A sepharose for 1 h at 4°C, centrifuged at 1000 × g for
5 min. Following several washes, the immunoprecipitated
proteins were resolved by sodium dodecyl sulfate-polyacr-
ylamide gel electrophoresis (SDS-PAGE). Oligomeric spe-
cies of Aβ in the immunoprecipitations were detected
using an Aβ oligomer specific mouse monoclonal anti-
body NU-2 [34].
Gel electrophoresis and Western blot analysis
SDS-PAGE and Western blot analysis were performed
according to the manufacturer's protocols (Invitrogen,
Carlsbad, CA). Samples were prepared in 1× lithium
dodecyl sulfate (LDS) buffer, applied to 4–12% bis-Tris
NuPAGE gels, resolved using MES running buffer and
transferred to 0.45 μm polyvinylidene difluoride (PVDF)
membranes. Membranes were subsequently blocked in
5% milk in PBS. Primary antibodies were diluted in 5%
milk with 0.1% Tween 20. Following overnight incuba-
tion at 4°C with primary antibodies, blots were washed
with PBS and detected utilizing anti-mouse or anti-rabbit
secondary antibodies conjugated to horse-radish peroxi-
dase (HRP) (1:20,000; #115-035-003 or #111-035-003,
Jackson ImmunoResearch Laboratories, West Grove, PA)
diluted in 5% milk with 0.1% Tween 20. To confirm equal
protein loading, mouse anti-GAPDH or rabbit anti-tubu-
lin antibodies were used. Bands were quantified utilizing
the AlphaEaseFC™ Software (Ver 4.0.1 – a part of Alpha
Innotech gel documentation system (Alpha Innotech Cor-
poration, USA)).
In-Cell western analysis
Expression of phospho-Akt/phospho-mTOR in primary
cortical neurons was quantified using the infrared-based
In-Cell Western (ICW) assay system as described by the
manufacturer (Li-Cor Biosciences, Lincoln, NE). Briefly,
primary cortical neurons were seeded into 96-well plates
at a density of 5 × 104 cells/well. At 21 DIV, cells were
treated with different concentrations of Aβ monomers or
Aβ oligomers. After 24 h, cells were washed with PBS,
fixed with 4% paraformaldehyde in PBS, blocked with 5%
normal goat serum (in PBS with 0.4% Triton-X100) and
incubated overnight at 4°C with different combinations
of primary antibodies; a rabbit polyclonal antibody
against phospho-AktSer473 and a rabbit monoclonal anti-
body against phospho-mTORSer2448. For normalization,
mouse anti-tubulin or rabbit anti-tubulin antibodies were
used. Cells were subsequently incubated with secondary
antibody mixtures (goat anti-mouse IRDye 700 and goat
anti-rabbit IRDye 800 (1:200; Rockland Immunochemi-
cals, Gilbertsville, PA) for 1 h at RT. Infrared signals were
measured and quantified in an Odyssey infrared imaging
system (Li-Cor Biosciences). The intensity of both chan-
nels was set at 8 and the focus offset was set at 3 mm for
plate scanning. The integrated intensity ratio for pAkt/
Tubulin or p-mTOR/Tubulin was calculated and the meanMolecular Neurodegeneration 2009, 4:14 http://www.molecularneurodegeneration.com/content/4/1/14
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± SEM for three independent experiments were used for
statistical analysis.
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